

**AMENDMENTS TO THE CLAIMS:**

This listing of the claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-20 (canceled)

21. (currently amended) A method of administering a multivalent composition, comprising:

a) providing:

- i) a subject having a B-cell lymphoma; and
- ii) a multivalent composition ~~for active-idiotype~~

~~immunotherapy~~ comprising at least two recombinant heavy chain variable regions of immunoglobulin molecules derived from said subject's B-cell lymphoma cells, wherein said at least two recombinant heavy chain variable regions differ by at least one idiotope; and

b) administering said multivalent composition ~~for active-idiotype~~  
~~immunotherapy~~ to said subject to invoke an immune response.

22.(currently amended) The method of Claim 21, wherein said composition ~~for active-idiotype~~  
~~immunotherapy~~ comprises at least two recombinant immunoglobulin molecules comprising said recombinant heavy chain variable regions derived from said lymphoma cells.

23.(currently amended) The method of Claim 21, wherein said composition ~~for active-idiotype~~  
~~immunotherapy~~ further comprises an adjuvant.

24.(previously presented) The method of Claim 23, wherein said adjuvant is SAF-1.

25.(previously presented) The method of Claim 21, wherein at least one of said at least two recombinant heavy chain variable regions is conjugated to a carrier protein.

26.(previously presented) The method of Claim 25, wherein said carrier protein is KLH.

27-32 (canceled)